BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/18/2021 11:27:35 AM | Browse: 772 | Download: 1899
 |
Received |
|
2021-01-28 14:59 |
|
Peer-Review Started |
|
2021-01-28 15:05 |
|
First Decision by Editorial Office Director |
|
2021-02-24 05:25 |
|
Return for Revision |
|
2021-02-25 01:25 |
|
Revised |
|
2021-03-10 14:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-04-26 08:51 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-04-26 11:37 |
|
Articles in Press |
|
2021-04-26 11:37 |
|
Edit the Manuscript by Language Editor |
|
2021-05-14 19:47 |
|
Typeset the Manuscript |
|
2021-05-18 01:47 |
|
Publish the Manuscript Online |
|
2021-05-18 11:27 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Minireviews |
| Article Title |
Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in COVID-19 patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BSc, MD, MSc, PhD, Associate Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6
rajavithi road, rachatawee, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
SARS-CoV-2; COVID-19; Hepatobiliary tissue; Angiotensin converting enzyme 2; Chronic liver disease; Common medications; Clinical outcome |
| Core Tip |
With more than 100 million confirmed cases worldwide, hepatobiliary injury has been reported in many coronavirus disease 2019 (COVID-19) patients. The association between COVID-19 and hepatobiliary injury refers to any hepatobiliary damage during disease progression and treatment in COVID-19 patients with or without chronic liver diseases or common medications. Angiotensin-converting enzyme 2 receptor may be a significant factor in hepatobiliary derangement due to its highly expressed cholangiocyte, and it is also an entry point of severe acute respiratory syndrome coronaviruses 2. Moreover, drug-induced liver injury and cytokine storm may be an added risk in severe clinical outcomes. Close monitoring of the liver function in COVID-19 patients is mandatory. |
| Publish Date |
2021-05-18 11:27 |
| Citation |
Leowattana W. Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in COVID-19 patients. World J Virol 2021; 10(3): 86-96 |
| URL |
https://www.wjgnet.com/2220-3249/full/v10/i3/86.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v10.i3.86 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
